Rigel Pharmaceuticals
RIGL
Get informed when a big investor buys or sells
+ FollowMarket Cap$872.37M
Close$
$-28.44
160.3% downside
Current Fair Value
160.3% downsideOvervalued by 160.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $872.37 Million |
|---|---|
| Enterprise Value | $879.48 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $20.4 |
| Beta | 1.2 |
| Outstanding Shares | 18,541,000 |
Return
| Return on Equity | 75.67% |
|---|---|
| Return on Assets | 61.78% |
| Return on Invested Capital | 20.18% |
Valuation & Multiples
| P/E Ratio | 2.67 |
|---|---|
| PEG | -3.76 |
| Price to Sales | 3.37 |
| Price to Book Ratio | 2.14 |
| Enterprise Value to Revenue | 3.18 |
| Enterprise Value to EBIT | 10.24 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.09
Average shareholder expectationRevenue Estimate
$55.27 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.92
Average shareholder expectationRevenue Estimate
$80.10 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5855▼ 15.77% |
|---|---|
| Total Calls | 100,600▲ 43.51% |
| Total Puts | 58,900▲ 13.05% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 89.82%▲ 2.91% |
|---|---|
| Total Invested | $646.62M▲ 49.43% |
| Investors Holding | 161▲ 6.00% |
ESG Score
No data
About Rigel Pharmaceuticals
CEO: Raul Rodriguez